Integra Therapeutics Opens its Capital to Columbus and Raises 1.5 Million

Integra Therapeutics raises more capital. The Spanish biotech company focused on the creation of gene-writing tools has closed a $1.67 million (€1.5 million) investment round with the support of venture capital manager Columbus Venture Partners, company sources have confirmed.

This capital is in addition to the $5 million (€4.5 million) that Integra Therapeutics raised in December last year from funds AdBio Partners, Invivo Capital, and Takeda Venture, closing its seed round.

Columbus VP’s investment was made through its third fund, Columbus Life Science Fund III FCR, launched in 2021 with a total budget of 120 million euros. Following the transaction, Damià Tormo, managing partner of Columbus VP, will join the board of Integra Therapeutics.

Discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

Integra Therapeutics will allocate the funds to the development of the FiCAT platform prototype and preclinical validation

The new resources will be used to support the development of the FiCAT platform prototype and preclinical validation with in vivo and ex vivo models. This platform is based on gene-writing technology and aims to solve the current technical limitations in gene therapy.

The Catalan company has also raised sufficient capital to manage the patent portfolio between 2022 and 2023. Subsequently, the company plans to open a Series A round to initiate regulatory approval and conduct clinical trials with patients. “We look forward to working together with the aim of getting more efficient and safer gene therapies to patients as soon as possible,” explained Avencia Sanchez- Mejias, co-founder, and CEO of Integra Therapeutics.

“We believe that Integra Therapeutics is set to become one of the world’s leading biotechs in gene writing in the coming years,” added Tormo.

The Barcelona-based company was founded in 2020 by researchers Marc Güell and Avencia Sánchez-Mejías

In February 2021, Integra Therapeutics added Professor George Church, a pioneer in human genome editing, to the company’s scientific advisory board. Church is an expert scientist in reading and writing DNA. He developed the first direct genomic sequencing method, helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005.

The Barcelona-based company was founded in 2020 by researchers Marc Güell and Avencia Sánchez-Mejías, from the Universitat Pompeu Fabra (UPF). The company currently has seven employees.

__

(Featured image by moerschy via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.